ADVENTRX to Present CoFactor Multiagent Therapy Data at AACR Annual Meeting
March 29 2007 - 7:00AM
PR Newswire (US)
SAN DIEGO, March 29 /PRNewswire-FirstCall/ -- ADVENTRX
Pharmaceuticals, Inc. (AMEX:ANX), a biopharmaceutical research and
development company focused on commercializing proprietary product
candidates for the treatment of cancer and infectious diseases,
announced today that results from preclinical studies of ANX-510
(CoFactor(R)) in combination with intravenous 5-fluorouracil (5-FU)
and capecitabine (Xeloda(R)), an oral prodrug of 5-FU, will be
presented at the American Association for Cancer Research (AACR)
Annual Meeting in Los Angeles, CA. The abstract entitled "Antitumor
activity and safety of a hybrid treatment regimen of
5,10-methylenetetrahydrofolate, 5-fluorouracil, and capecitabine in
a colorectal tumor xenograft model" will be presented on Tuesday,
April 17 at 1:00 p.m. local time. About CoFactor CoFactor (ANX-510)
is a folate-based biomodulator drug designed to replace leucovorin
as the preferred method to enhance the activity and reduce
associated toxicity of the widely used cancer chemotherapy
5-fluorouracil (5-FU). In comparison to leucovorin, CoFactor
creates more stable binding of the active form of 5-FU to the
target enzyme, thymidylate synthase (TS). CoFactor bypasses the
metabolic pathway required by leucovorin to deliver the active form
of folate, allowing 5-FU to work more effectively. CoFactor is in
Phase 3 and Phase 2b clinical trials for the treatment of
metastatic colorectal cancer, as well as in a Phase 2 clinical
trial for the treatment of advanced breast cancer. About ADVENTRX
Pharmaceuticals ADVENTRX Pharmaceuticals is a biopharmaceutical
research and development company focused on commercializing
proprietary product candidates for the treatment of cancer and
infectious diseases. The Company seeks to improve the performance
and safety of existing treatments by addressing significant
problems such as drug metabolism, bioavailability, excessive
toxicity and treatment resistance. More information can be found on
the Company's web site at http://www.adventrx.com/. Forward Looking
Statement ADVENTRX cautions you that statements included in this
press release that are not a description of historical facts are
forward-looking statements that involve risks, uncertainties,
assumptions and other factors that, if they do not materialize or
prove to be accurate, could cause ADVENTRX's results to differ
materially from historical results or those expressed or implied by
such forward-looking statements. The potential risks and
uncertainties that could cause actual results for our CoFactor
studies to differ materially include, but are not limited to: the
validity of research results; uncertainties inherent in the drug
development process; the timing and success of clinical trials; the
receipt of necessary approvals from the FDA and other regulatory
agencies; and other risks and uncertainties more fully described in
ADVENTRX's press releases and public filings with the Securities
and Exchange Commission. ADVENTRX's public filings with the
Securities and Exchange Commission are available at
http://www.sec.gov/. ADVENTRX does not intend to update any
forward-looking statement, including as set forth in this press
release, to reflect events or circumstances arising after the date
on which it was made. DATASOURCE: ADVENTRX Pharmaceuticals, Inc.
CONTACT: Investors, Ioana C. Hone of ADVENTRX Pharmaceuticals,
+1-858-552-0866; or Amy Martini of WeissComm Partners,
+1-212-301-7223, for ADVENTRX Pharmaceuticals, Inc. Web site:
http://www.adventrx.com/ Company News On-Call:
http://www.prnewswire.com/gh/cnoc/comp/920134.html
Copyright
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jul 2023 to Jul 2024